<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439465</url>
  </required_header>
  <id_info>
    <org_study_id>D0717</org_study_id>
    <nct_id>NCT00439465</nct_id>
  </id_info>
  <brief_title>Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma</brief_title>
  <official_title>Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the administration of highly effective
      &quot;killer&quot; cells (cytotoxic T cells), along with Interleukin-2 (IL-2) and Recombinant Human
      Granulocyte Colony Stimulating Factor (GM-CSF) immediately following Autologous Peripheral
      Blood Stem Cell Transplantation (APBSCT) will enhance anti-tumor immune reconstitution and
      improve outcome of Multiple Myeloma patients.

      The overall hypothesis of this proposal is that immediately following APBSCT the immune
      reconstitution is optimal to administer &quot;killer&quot; cells, combined with the administration of
      IL-2 and GM-CSF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 30, 2012</completion_date>
  <primary_completion_date type="Actual">October 15, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events in All Subjects</measure>
    <time_frame>From initiation of treatment on protocol until Day 100</time_frame>
    <description>To establish the safety (toxicity) of myeloma patients treated with high dose melphalan, autologous peripheral blood stem cell transplantation (APBSCT) &amp; adoptive transfer of cytotoxic effector cells with Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Increased CD3+CD8+, CD8+ and CD56+ Concentrations Between Day 15 Post-Transplant and Days 21 to 28 Post-transplant</measure>
    <time_frame>Day 15 post-transplant and between days 21 to 28 post-transplant</time_frame>
    <description>To demonstrate that the effector cell infusions result in a clinical effect, phenotypic analyses of blood samples using flow cytometry will be performed prior to, and after each infusion, focusing on the CD8 + populations (CD3+CD8+, CD8+CD56+). As a complement to flow cytometry, the following assays will be used to identify cell subset precursor frequencies, subset proliferation, and cytokine production:
Dye Dilution Proliferation Assay (DDPA) 36 - Evaluation of CD8+ T Cell Precursors
ELISPOT-Quantifying cytokine producing T cells:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery of Absolute Neutrophil Count</measure>
    <time_frame>From initiation of treatment on protocol until Day 100</time_frame>
    <description>To establish the time to engraftment of myeloma patients treated with high dose melphalan, APBSCT&amp; adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery of Platelet Count</measure>
    <time_frame>From initiation of treatment on protocol until Day 100</time_frame>
    <description>To establish the time to engraftment of myeloma patients treated with high dose melphalan, APBSCT&amp; adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Disease Response to Treatment</measure>
    <time_frame>From initiation of treatment on protocol until Day 100</time_frame>
    <description>To establish the disease response of myeloma patients treated with high dose melphalan, APBSCT&amp; adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Increased Expression of DAP10 and NKG2D on the CD8 Cell Population</measure>
    <time_frame>Pre-transplant and following the third and fourth cellular infusions</time_frame>
    <description>Isolate CD3+CD8+ and CD8+CD56+ from patients' blood following transplant.
Identify NKG2D and DAP10 expression.
Determine the mechanism of tumor cell killing and the relationship to NKG2D or DAP 10 expression.
After isolating CD8+ cells from patient's blood samples using the AutoMACS, we will evaluate the expression of NKG2D and DAP10 on all CD8+ cells (CD3+CD8+ and CD8+CD56+cells) pre-transplant (Baseline) and following the third and fourth cellular infusions using phenotypic analysis. We postulate the increased expression of both DAP10 and NKG2D on the CD8 population immediately following APSCT and effector cell infusions when compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Methods of Tumor Cell Killing of the in Vivo CD8+ Cells: Cytotoxicity Assays, Blocking Experiments, Analysis of T-cell Receptor (TCR)</measure>
    <time_frame>Pre-transplant and following the third and fourth cellular infusions.</time_frame>
    <description>We will isolate the CD8+ populations (CD3+CD8+, CD8+CD56+) using the Auto MACS (Miltenyi) and then identify the mechanisms of tumor cell killing by the CD8+ cells obtained pre-transplant (Baseline) and following the third and fourth cellular infusions. We will examine mechanisms of tumor cell killing through NKG2D receptor, major histocompatibility complex (MHC) Class I molecules or through the T cell receptor. We postulate the CD8+ cells obtained from patient's blood will kill tumor cells both via MHC Class I and through the NKG2D receptor.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Myeloma</condition>
  <condition>Transplant-eligible Patients</condition>
  <arm_group>
    <arm_group_label>Ex-vivo expanded effector cells</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Infusing IL-2 and GM-CSF post-Hematopoietic Stem Cell Transplant (HSCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ex-vivo expanded effector cells</intervention_name>
    <description>This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.</description>
    <arm_group_label>Ex-vivo expanded effector cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Multiple Myeloma:

          -  Patients must meet criteria for diagnosis of Multiple Myeloma.

          -  Patient must meet either criterion listed below:

               -  Stage I, II, or III newly diagnosed multiple myeloma

               -  Progressive or relapsed disease in partial response (PR) or complete response
                  (CR)

               -  Primary refractory disease.

               -  Relapsed refractory disease.

               -  Patients may have received a prior autologous transplant.

          -  The patients must have recovered from all serious and life threatening effects of
             previous treatment at the time of study entry (unless this abnormality is believed to
             be due to the underlying myeloma).

          -  The patient must have adequate bone marrow function, i.e. a total white blood cell
             count (WBC) of &gt; 2,000/ul, a Hemoglobin (Hgb) of &gt; 7 gm/dl, and a platelet count of &gt;
             50,000/ul, unless this abnormality is believed to be due to the underlying myeloma.

          -  The patient must have adequate liver function, i.e. bilirubin &lt;2.0 mg/dl, aspartate
             aminotransferase (SGOT), alanine aminotransferase (SGPT) not greater than 2 times the
             upper normal limit (unless this abnormality is believed to be due to the underlying
             myeloma).

          -  The patient must have adequate renal function, i.e. serum creatinine &lt; 3.0 mg/dl,
             and/or creatinine clearance &gt;50 ml/min. This eligibility criterion is excluded if
             renal insufficiency is believed to be secondary to myeloma.

          -  Age &gt;18 years and &lt; 75 years old

          -  The patient must have a Karnofsky status &gt; 80%

          -  Patients must have a life expectancy of at least 12 weeks

          -  Left ventricular ejection fraction of &gt; 45% by radionuclide scan or echocardiography

          -  Pulmonary function tests: forced vital capacity, Diffusing capacity of the lungs for
             carbon monoxide (DLCO) and expiratory volume in one second (FEV1) must be &gt; 50% of
             predicted

          -  No significant co-morbid medical or psychiatric illness which would significantly
             compromise the patient's clinical care and chances of survival.

          -  Informed written consent must be obtained. Patients must be able to give informed
             consent as a prerequisite to this procedure. The Informed Consent form will become
             part of his/her permanent record and a copy will be given to the patient

        Exclusion Criteria:

          -  Medical, social, or psychological factors which would prevent the patient from
             receiving or cooperating with the full course of therapy.

          -  Evidence on physical exam, lumbar puncture, computed tomography (CT), or magnetic
             resonance imaging (MRI) scan of central nervous system (CNS) involvement with
             malignancy

          -  Any clinically significant cardiac disease (angina, myocardial infarction, congestive
             heart failure, ventricular arrhythmias requiring therapy) or clinically significant
             obstructive/restrictive pulmonary disease

          -  Serology positive for human immunodeficiency virus (HIV) or human T-lymphotropic virus
             (HTLVI)

          -  Active hepatitis B or C

          -  History of seizures

          -  Concurrent or expected need for therapy with corticosteroids

          -  Active connective tissue disease

          -  Current &quot;clinically significant&quot; pleural effusion, pericardial effusion, or ascites

          -  Positive pregnancy test or presence of lactation

          -  Collection of fewer than 1 x 106 cluster of differentiation 34 positive (CD34+)
             cells/kg (peripheral blood stem cells). If the apheresis collection is inadequate
             based on this criteria, the patient will be removed from protocol and a marrow harvest
             may be performed

          -  A history of a second malignancy (other then squamous cell/ basal cell carcinoma of
             the skin or cervical dysplasia) must be reviewed by the Principal Investigator, before
             inclusion or exclusion in the study. Based upon the PI's review, this patient may be
             eligible (i.e., distant past history of a malignancy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Meehan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 21, 2007</study_first_submitted>
  <study_first_submitted_qc>February 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2007</study_first_posted>
  <results_first_submitted>April 9, 2018</results_first_submitted>
  <results_first_submitted_qc>March 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2019</results_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Kenneth Meehan</investigator_full_name>
    <investigator_title>Director, Bone Marrow Transplant Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ex-vivo Expanded Effector Cells</title>
          <description>Infusing Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF)post-Hematopoietic stem cell transplant (HSCT)
Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ex-vivo Expanded Effector Cells</title>
          <description>Infusing IL-2 and GM-CSF post-HCST
Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="42" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events in All Subjects</title>
        <description>To establish the safety (toxicity) of myeloma patients treated with high dose melphalan, autologous peripheral blood stem cell transplantation (APBSCT) &amp; adoptive transfer of cytotoxic effector cells with Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF).</description>
        <time_frame>From initiation of treatment on protocol until Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ex-vivo Expanded Effector Cells</title>
            <description>Infusing IL-2 and GM-CSF post-Hematopoietic Stem-Cell Transplant (HSCT) Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events in All Subjects</title>
          <description>To establish the safety (toxicity) of myeloma patients treated with high dose melphalan, autologous peripheral blood stem cell transplantation (APBSCT) &amp; adoptive transfer of cytotoxic effector cells with Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Increased CD3+CD8+, CD8+ and CD56+ Concentrations Between Day 15 Post-Transplant and Days 21 to 28 Post-transplant</title>
        <description>To demonstrate that the effector cell infusions result in a clinical effect, phenotypic analyses of blood samples using flow cytometry will be performed prior to, and after each infusion, focusing on the CD8 + populations (CD3+CD8+, CD8+CD56+). As a complement to flow cytometry, the following assays will be used to identify cell subset precursor frequencies, subset proliferation, and cytokine production:
Dye Dilution Proliferation Assay (DDPA) 36 - Evaluation of CD8+ T Cell Precursors
ELISPOT-Quantifying cytokine producing T cells:</description>
        <time_frame>Day 15 post-transplant and between days 21 to 28 post-transplant</time_frame>
        <population>Sixteen out of nineteen subject samples were analyzed. Three subject's samples were not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ex-vivo Expanded Effector Cells</title>
            <description>Infusing IL-2 and GM-CSF post-HCST
Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Increased CD3+CD8+, CD8+ and CD56+ Concentrations Between Day 15 Post-Transplant and Days 21 to 28 Post-transplant</title>
          <description>To demonstrate that the effector cell infusions result in a clinical effect, phenotypic analyses of blood samples using flow cytometry will be performed prior to, and after each infusion, focusing on the CD8 + populations (CD3+CD8+, CD8+CD56+). As a complement to flow cytometry, the following assays will be used to identify cell subset precursor frequencies, subset proliferation, and cytokine production:
Dye Dilution Proliferation Assay (DDPA) 36 - Evaluation of CD8+ T Cell Precursors
ELISPOT-Quantifying cytokine producing T cells:</description>
          <population>Sixteen out of nineteen subject samples were analyzed. Three subject's samples were not available for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <title>Increase</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Increase</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 21-28</title>
              <category_list>
                <category>
                  <title>Increase</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Increase</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recovery of Absolute Neutrophil Count</title>
        <description>To establish the time to engraftment of myeloma patients treated with high dose melphalan, APBSCT&amp; adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.</description>
        <time_frame>From initiation of treatment on protocol until Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ex-vivo Expanded Effector Cells</title>
            <description>Infusing IL-2 and GM-CSF post-HCST
Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recovery of Absolute Neutrophil Count</title>
          <description>To establish the time to engraftment of myeloma patients treated with high dose melphalan, APBSCT&amp; adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="12" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recovery of Platelet Count</title>
        <description>To establish the time to engraftment of myeloma patients treated with high dose melphalan, APBSCT&amp; adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.</description>
        <time_frame>From initiation of treatment on protocol until Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ex-vivo Expanded Effector Cells</title>
            <description>Infusing IL-2 and GM-CSF post-HCST
Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recovery of Platelet Count</title>
          <description>To establish the time to engraftment of myeloma patients treated with high dose melphalan, APBSCT&amp; adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="10" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Disease Response to Treatment</title>
        <description>To establish the disease response of myeloma patients treated with high dose melphalan, APBSCT&amp; adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.</description>
        <time_frame>From initiation of treatment on protocol until Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ex-vivo Expanded Effector Cells</title>
            <description>Infusing IL-2 and GM-CSF post-HCST
Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Disease Response to Treatment</title>
          <description>To establish the disease response of myeloma patients treated with high dose melphalan, APBSCT&amp; adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Good Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Increased Expression of DAP10 and NKG2D on the CD8 Cell Population</title>
        <description>Isolate CD3+CD8+ and CD8+CD56+ from patients' blood following transplant.
Identify NKG2D and DAP10 expression.
Determine the mechanism of tumor cell killing and the relationship to NKG2D or DAP 10 expression.
After isolating CD8+ cells from patient's blood samples using the AutoMACS, we will evaluate the expression of NKG2D and DAP10 on all CD8+ cells (CD3+CD8+ and CD8+CD56+cells) pre-transplant (Baseline) and following the third and fourth cellular infusions using phenotypic analysis. We postulate the increased expression of both DAP10 and NKG2D on the CD8 population immediately following APSCT and effector cell infusions when compared to baseline.</description>
        <time_frame>Pre-transplant and following the third and fourth cellular infusions</time_frame>
        <population>Sixteen out of nineteen participants samples were analyzed. Three participants' samples were not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ex-vivo Expanded Effector Cells</title>
            <description>Infusing IL-2 and GM-CSF post-Hematopoietic Stem Cell Transplant (HSCT)
Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Increased Expression of DAP10 and NKG2D on the CD8 Cell Population</title>
          <description>Isolate CD3+CD8+ and CD8+CD56+ from patients' blood following transplant.
Identify NKG2D and DAP10 expression.
Determine the mechanism of tumor cell killing and the relationship to NKG2D or DAP 10 expression.
After isolating CD8+ cells from patient's blood samples using the AutoMACS, we will evaluate the expression of NKG2D and DAP10 on all CD8+ cells (CD3+CD8+ and CD8+CD56+cells) pre-transplant (Baseline) and following the third and fourth cellular infusions using phenotypic analysis. We postulate the increased expression of both DAP10 and NKG2D on the CD8 population immediately following APSCT and effector cell infusions when compared to baseline.</description>
          <population>Sixteen out of nineteen participants samples were analyzed. Three participants' samples were not available for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increased abs. NKG2D+CD3+CD8 Tcells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased abs. NKG2D+CD3-CD56+ T cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Methods of Tumor Cell Killing of the in Vivo CD8+ Cells: Cytotoxicity Assays, Blocking Experiments, Analysis of T-cell Receptor (TCR)</title>
        <description>We will isolate the CD8+ populations (CD3+CD8+, CD8+CD56+) using the Auto MACS (Miltenyi) and then identify the mechanisms of tumor cell killing by the CD8+ cells obtained pre-transplant (Baseline) and following the third and fourth cellular infusions. We will examine mechanisms of tumor cell killing through NKG2D receptor, major histocompatibility complex (MHC) Class I molecules or through the T cell receptor. We postulate the CD8+ cells obtained from patient's blood will kill tumor cells both via MHC Class I and through the NKG2D receptor.</description>
        <time_frame>Pre-transplant and following the third and fourth cellular infusions.</time_frame>
        <population>Autologous myeloma cells were isolated for only 4 study participants. There is no information on the remaining participant provided.</population>
        <group_list>
          <group group_id="O1">
            <title>Ex-vivo Expanded Effector Cells</title>
            <description>Infusing Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF)post-Hematopoietic stem cell transplant (HSCT)
Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Methods of Tumor Cell Killing of the in Vivo CD8+ Cells: Cytotoxicity Assays, Blocking Experiments, Analysis of T-cell Receptor (TCR)</title>
          <description>We will isolate the CD8+ populations (CD3+CD8+, CD8+CD56+) using the Auto MACS (Miltenyi) and then identify the mechanisms of tumor cell killing by the CD8+ cells obtained pre-transplant (Baseline) and following the third and fourth cellular infusions. We will examine mechanisms of tumor cell killing through NKG2D receptor, major histocompatibility complex (MHC) Class I molecules or through the T cell receptor. We postulate the CD8+ cells obtained from patient's blood will kill tumor cells both via MHC Class I and through the NKG2D receptor.</description>
          <population>Autologous myeloma cells were isolated for only 4 study participants. There is no information on the remaining participant provided.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Autologous Myeloma Cells</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increased tumor lysis</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure of tumor lysis</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral blood mononuclear cells</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increased tumor lysis</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure of tumor lysis</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the start of treatment until 100 days post-treatment for all subjects. Total time of adverse event collection for the study was January 2007 through March 2010</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ex-vivo Expanded Effector Cells</title>
          <description>Infusing IL-2 and GM-CSF post-HCST
Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Mucositis - oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased liver function tests</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Moderate infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Severe infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kenneth Meehan, MD</name_or_title>
      <organization>Dartmouth-Hitchcock Medical Center</organization>
      <phone>603-650-6432</phone>
      <email>Kenneth.R.Meehan@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

